Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

Fig. 3

Twenty-four weeks efficacy of intravenous tacrolimus. a Relapse-free survival at 24 weeks. Among the patients who achieved remission at 2 weeks, oral and intravenous tacrolimus groups showed similar 24-week relapse-free survival rates of 60.0% ± 21.9% and 79.3% ± 7.5%, respectively. b Colectomy-free survival at 24 weeks. The 24-week colectomy-free survival rates in patients treated with intravenous tacrolimus (76.8% ± 5.3%) were better than the survival rates in patients treated with oral TAC (53.6% ± 10.8%)

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us